A detailed history of Alliancebernstein L.P. transactions in Hille Vax, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 21,850 shares of HLVX stock, worth $38,456. This represents 0.0% of its overall portfolio holdings.

Number of Shares
21,850
Previous 17,140 27.48%
Holding current value
$38,456
Previous $285,000 10.53%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$11.86 - $15.93 $55,860 - $75,030
4,710 Added 27.48%
21,850 $315,000
Q1 2024

May 14, 2024

BUY
$14.15 - $19.75 $36,507 - $50,955
2,580 Added 17.72%
17,140 $285,000
Q4 2023

Feb 14, 2024

BUY
$10.35 - $17.11 $4,657 - $7,699
450 Added 3.19%
14,560 $233,000
Q3 2023

Nov 14, 2023

BUY
$11.59 - $16.7 $22,716 - $32,732
1,960 Added 16.13%
14,110 $189,000
Q2 2023

Aug 15, 2023

BUY
$12.93 - $18.76 $157,099 - $227,934
12,150 New
12,150 $208,000

Others Institutions Holding HLVX

About HilleVax, Inc.


  • Ticker HLVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,427,200
  • Market Cap $58.8M
  • Description
  • HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
More about HLVX
Track This Portfolio

Track Alliancebernstein L.P. Portfolio

Follow Alliancebernstein L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.